Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial

Autor: Aydinlar, Suzan, Courtley, James, Douglas-Bailey, Maggie, Graves, Elizabeth, Holden, Natasha, Hutton, Jane, Hutton, Paul, Irving, Susan, Jackson, Clare, Lebert, Toyah, Mander, Helen, McCartney, Laura, Munro-Clark, Trevor, Murphy, Elizabeth Kim, Spanswick, Mairi, Steele, Ann, Tip, Liesbeth, Tully, Sarah, Morrison, Anthony P, Pyle, Melissa, Gumley, Andrew, Schwannauer, Matthias, Turkington, Douglas, MacLennan, Graeme, Norrie, John, Hudson, Jemma, Bowe, Samantha E, French, Paul, Byrne, Rory, Syrett, Suzy, Dudley, Robert, McLeod, Hamish J, Griffiths, Helen, Barnes, Thomas R E, Davies, Linda, Kingdon, David

Publikováno v: In The Lancet Psychiatry August 2018 5(8):633-643

Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial

Autor: Morrison, Anthony P, Pyle, Melissa, Gumley, Andrew, Schwannauer, Matthias, Turkington, Douglas, MacLennan, Graeme, Norrie, John, Hudson, Jemma, Bowe, Samantha E, French, Paul, Byrne, Rory, Syrett, Suzy, Dudley, Robert, McLeod, Hamish J, Griffiths, Helen, Barnes, Thomas R E, Davies, Linda, Kingdon, David, Aydinlar, Suzan, Courtley, James, Douglas-Bailey, Maggie, Graves, Elizabeth, Holden, Natasha, Hutton, Jane, Hutton, Paul, Irving, Susan, Jackson, Clare, Lebert, Toyah, Mander, Helen, McCartney, Laura, Munro-Clark, Trevor, Murphy, Elizabeth Kim, Spanswick, Mairi, Steele, Ann, Tip, Liesbeth, Tully, Sarah

Publikováno v: Morrison, A P, Pyle, M, Gumley, A, Schwannauer, M, Turkington, D, Maclennan, G, Norrie, J, Hudson, J, Bowe, S E, French, P, Byrne, R, Syrett, S, Dudley, R, Mcleod, H J, Griffiths, H, Barnes, T R E, Davies, L, Kingdon, D, Aydinlar, S, Courtley, J, Douglas-bailey, M, Graves, E, Holden, N, Hutton, J, Hutton, P, Irving, S, Jackson, C, Lebert, T, Mander, H, Mccartney, L, Munro-clark, T, Murphy, E K, Spanswick, M, Steele, A, Tip, L & Tully, S 2018, ' Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial ', The Lancet Psychiatry, vol. 5, no. 8, pp. 633-643 . https://doi.org/10.1016/S2215-0366(18)30184-6

BackgroundAlthough clozapine is the treatment of choice for treatment-refractory schizophrenia, 30–40% of patients have an insufficient response, and others are unable to tolerate it. Evidence for any augmentation strategies is scarce. We aimed to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a69300d42a3bfc48692ecaca7e27a10e
http://www.scopus.com/inward/record.url?scp=85053834197&partnerID=8YFLogxK